We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Stratagene and Rosetta Inpharmatics Announce Alliance

By HospiMedica staff writers
Posted on 20 Sep 2006
Stratagene Corp. More...
(La Jolla, CA, USA) and Rosetta Inpharmatics, LLC (Seattle, WA, USA), a wholly-owned subsidiary of Merck & Co., Inc., have entered into a joint development-and-license agreement. The companies will develop an RNA purification system for use in molecular diagnostics and research applications.

Under the terms of the agreement, Stratagene and Rosetta will jointly develop a proprietary instrument and a single-use consumable that will be manufactured and commercialized by Stratagene. These products will be sold to Stratagene's current customer base and companies engaged in pharmacogenomics. Financial terms of the agreement were not disclosed.

The companies plan to create an automated solution for the isolation of nucleic acids from a variety of clinical samples. Nucleic acid purification allows scientists to separate RNA contained in biologic samples. Clinicians and researchers can use the purified RNA to perform gene expression analysis and other functions within molecular diagnostics.

"This agreement with Rosetta Inpharmatics is a significant opportunity for Stratagene and marks another milestone in our molecular diagnostics strategy,” said Joseph A. Sorge, M.D., president and CEO of Stratagene. "We believe we have a unique opportunity to create and introduce a differentiated product that will automate the RNA purification process and provide consistent, reproducible results. These two characteristics are critical capabilities in gene expression analysis.”

Stratagene is a developer, manufacturer, and marketer of specialized life science research and diagnostic products. The company's diagnostic unit develops and manufactures products for urinalysis as well as automated instruments and reagent systems that use blood samples to test for more than 1,000 different allergies and autoimmune disorders. In addition, by combining its expertise in diagnostics and molecular biology, the company is pursuing opportunities to expand its product portfolio to include molecular diagnostic kits and instrumentation.



Related Links:
Stratagene
Rosetta Inpharmatics

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Multi-Chamber Washer-Disinfector
WD 390
New
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.